Major depressive disorder (MDD) is characterized by persistent depressed mood, loss of
interest or pleasure in previously enjoyable activities, recurrent thoughts of death, and …

Patients with schizophrenia experience a broad range of detrimental health outcomes
resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse …

Objective: To test esmethadone (REL-1017) as adjunctive treatment in patients with major
depressive disorder (MDD) and inadequate response to standard antidepressants. Methods …

ABSTRACT Introduction Generalized Anxiety Disorder (GAD) is a common psychiatric
condition, characterized by the presence of general apprehensiveness and excessive worry …

Background Schizophrenia is a disabling disorder that profoundly affects functioning and
quality of life. While available antipsychotics have improved outcomes for patients with …

Alternatives to traditional categorical diagnoses have been proposed to improve the validity
and utility of psychiatric nosology. This paper continues the companion review of an …

Introduction Maintenance antipsychotic treatment improves multiple outcomes in people with
schizophrenia. These benefits are challenged by medication nonadherence, which is a …

The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine
(esketamine) rapidly induce antidepressant effects and promote sustained actions following …

The moniker “psychedelic” was coined in 1956 by the British Psychiatrist, Humphrey
Osmond, referring to “mind manifesting.” Clinically, mind manifesting referred to a subjective …

Depression is a heterogeneous, complex and multidimensional disorder, representing one
of the leading causes of disability worldwide. The final aim of the management of patients is …